No platinum chemotherapy for nasopharyngeal cancer
Part of Cancer clinical trials.
This trial tests a new treatment plan for nasopharyngeal cancer that avoids platinum-based chemotherapy, which can have harsh side effects. It may help patients with stage II or III disease by using other drugs to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been newly diagnosed with nasopharyngeal cancer (a type of throat cancer).
- Your cancer is stage II or III, but not a specific subtype called T3N0.
- You are generally healthy and able to care for yourself (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and heart function are within normal limits.
- You are not pregnant or breastfeeding and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This study tests whether adding an investigational drug (anlotinib) to standard chemotherapy and radiation, along with immunotherapy, can better control high-risk nasopharyngeal cancer. It aims to see if this combination reduces the chance of the cancer coming back.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.